Study of a new drug for PNH patients with anemia despite current treatment
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a body mass index (BMI) of 18 or higher.
- You have been diagnosed with PNH and at least 10% of your red blood cells have the PNH defect.
- You have been on a stable dose of a medicine like eculizumab (anti-C5 antibody) for at least 6 months.
- Your hemoglobin level has been below 10 g/dL (100 g/L) on at least two tests in the past 4 months and still low at screening.
- You must be willing to get vaccines for certain bacteria (meningococcus, pneumococcus, Haemophilus influenzae) before starting the study drug.
- You are not currently taking any other investigational drugs and do not have a history of certain infections or conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new pill (FXS6837) compared to the standard IV medicine eculizumab for people with PNH. The study lasts 24 weeks and aims to see if the new pill works better or as well and has fewer side effects.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.